source
- Roivant's brepocitinib cuts steroid use in non-infectious uveitis in Phase 3 trialsRoivant Sciences and its subsidiary Priovant reported that their TYK2/JAK inhibitor brepocitinib met all primary and secondary endpoints in two identical Phase 3 studies (Clarity‑1 and Clarity‑2) i…
- U.S. proposes rule tightening review of biotech licensing deals with Chinese firmsThe U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…